|Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ...|
ALLN-177 is currently being developed for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones. Treatment with ALLN-177 resulted in a statistically significant reduction of urinary oxalate excretion in ...
Business Wire (press release) - Thu, 12 Nov 2015 04:00
|Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN ...|
ALLN-177 is an orally-administered, recombinant oxalate-degrading enzyme in development for the chronic management of hyperoxaluria and kidney stones (nephrolithiasis). ALLN-177 targets oxalate in the gastrointestinal tract, in an effort to reduce the ...
Business Wire (press release) - Wed, 04 Nov 2015 04:00
|Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary ...|
The Phase 2b randomized, crossover study (Clinicaltrials.gov identifier NCT02503345) will evaluate the safety, tolerability and efficacy of three different doses of ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria.
Business Wire (press release) - Tue, 04 Aug 2015 05:22
|Dicerna Files IND Application for Primary Hyperoxaluria Drug|
shares were up almost 7.0% immediately after the company announced that it has submitted an Investigational New Drug (IND) application to the FDA for DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1). However, most of the gains were lost ...
Nasdaq - Fri, 04 Sep 2015 11:45
|Rose Parade Float to Carry Messages from the Heart: Honors Organ, Eye and ...|
For a fifth year, families gathered with Community Healthcare System staff members, Gift of Hope Organ & Tissue Donor Network representatives and Indiana Lions Eye Bank officials to honor the area's organ, eye and tissue donors. The annual Donate Life ...
ValpoLife.com - Wed, 25 Nov 2015 11:52
|Analysts Set $23.00 Target Price for Dicerna Pharmaceuticals (NASDAQ:DRNA)|
Its current development programs include Dacryocystorhinostomy (DCR)-PH1 for Primary Hyperoxaluria Type 1 (PH1), Additional Liver Targets, DCR-MYC for MYC-related cancers and KRAS Program. Dicerna's discovery approach is based on ...
Voice Chronicle - Mon, 23 Nov 2015 09:48
|Dicerna Announces Third Quarter 2015 Financial and Operational Results|
DCR-PH1: DCR-PH1 is a DsiRNA-EX-based therapeutic candidate for Primary Hyperoxaluria Type 1 (PH1), a severe, rare genetic disease of liver metabolism that often results in life-threatening damage to the kidneys. In a genetic mouse model of PH1, ...
MarketWatch - Tue, 10 Nov 2015 13:11
|Dicerna Pharmaceuticals Shares Up 4% Following Earnings Beat (DRNA)|
Dakota Financial News - Wed, 11 Nov 2015 10:56
|Dicerna Pharmaceuticals (NASDAQ:DRNA) Receives Outperform Rating From Leerink ...|
Risers & Fallers - Wed, 11 Nov 2015 08:52
|Dicerna Pharmaceuticals (DRNA) Releases Quarterly Earnings Results, Beats ...|
MidSouth Newz - Tue, 10 Nov 2015 18:15
|Alnylam Pharmaceuticals Keeping Multiple High-Potential Programs Moving Forward|
The company also accelerated the development of ALN-GO1, a drug for the ultra-rare genetic condition primary hyperoxaluria type 1 (or PH1). This disease leads to kidney failure in about 80% of patients, with most of the effects occurring when people ...
Seeking Alpha - Thu, 12 Nov 2015 08:18